President & CEO, Akari Therapeutics Plc
Biotech CEO developing and delivering transformative therapies to patients with rare diseases. More than two decades as a global leader driving long-term, sustainable value to stakeholders, including investors. Experienced director currently serving on the board of two public biopharmaceutical companies. Extensive track record managing successful cultural and strategic transformations, creating effective governance frameworks, and providing leadership for spinoffs and integrations. Empowers and inspires high-performing, agile teams to solve problems, innovate solutions, build unique capabilities and add to the overall knowledge base in emerging biotech sectors. Strong global and U.S. background in strategic, cross-functional leadership roles spanning finance, business operations and commercial, including the successful launches of several novel therapies for rare diseases. A thought leader and vocal advocate for the advancement of medicines to address significant and urgent unmet needs in rare diseases. Founding member of the ARM Action for Equality Task Force. Frequent author and panelist in industry forums calling for a redefinition of best regulatory, manufacturing and commercial practices to enable emerging biotechnologies and therapies.